The Putative Tumour Suppressor MicroRNA-124 Modulates Hepatocellular Carcinoma Cell Aggressiveness by Repressing ROCK2 and EZH2
Overview
Authors
Affiliations
Background: Recent profile studies of microRNA (miRNA) expression have documented a deregulation of miRNA (miR-124) in hepatocellular carcinoma (HCC).
Objective: To determine the status of miR-124 expression and its underlying mechanisms in the pathogenesis of HCC.
Methods: The expression levels of miR-124 were first examined in HCC cell lines and tumour tissues by real-time PCR. The in vitro and in vivo functional effect of miR-124 was examined further. A luciferase reporter assay was conducted to confirm target associations.
Results: The expression levels of miR-124 were frequently reduced in HCC cells and tissues, and low-level expression of miR-124 was significantly associated with a more aggressive and/or poor prognostic phenotype of patients with HCC (p<0.05). In HCC cell lines, stable overexpression of miR-124 was sufficient to inhibit cell motility and invasion in vitro, and suppress intrahepatic and pulmonary metastasis in vivo. In addition, ectopic overexpression of miR-124 in HCC cells inhibited epithelial-mesenchymal cell transition, formation of stress fibres, filopodia and lamellipodia. Further studies showed that miR-124 could directly target the 3'-untranslated region (3'-UTR) of both ROCK2 and EZH2 mRNAs, and suppress their mRNA and protein expressions. These findings suggest that miR-124 plays a critical role in regulating cytoskeletal events and epithelial-mesenchymal cell transition and, ultimately, inhibits the invasive and/or metastatic potential of HCC, probably by its direct target on ROCK2 and EZH2 genes. These results provide functional and mechanistic links between the tumour suppressor miRNA-124 and the two oncogenes ROCK2 and EZH2 on the aggressive nature of HCC.
Conclusion: These data highlight an important role for miR-124 in the regulation of invasion and metastasis in the molecular aetiology of HCC, and suggest a potential application of miR-124 in prognosis prediction and cancer treatment.
Jeng L, Chan W, Teng C Discov Oncol. 2025; 16(1):281.
PMID: 40056315 PMC: 11890906. DOI: 10.1007/s12672-025-02043-y.
Lopes C, Almeida T, Macedo-Silva C, Costa J, Paulino S, Jeronimo C Clin Epigenetics. 2024; 16(1):113.
PMID: 39169394 PMC: 11340155. DOI: 10.1186/s13148-024-01712-z.
MicroRNA as Key Players in Hepatocellular Carcinoma: Insights into Their Role in Metastasis.
Saadh M, Hussain Q, Alazzawi T, Fahdil A, Athab Z, Yarmukhamedov B Biochem Genet. 2024; .
PMID: 39103713 DOI: 10.1007/s10528-024-10897-0.
Farsi N, Naghipour B, Shahabi P, Safaralizadeh R, Hajiasgharzadeh K, Dastmalchi N Clin Exp Hepatol. 2024; 9(4):307-319.
PMID: 38774201 PMC: 11103798. DOI: 10.5114/ceh.2023.131669.
Chen J, He F, Peng H, Guo J Front Mol Biosci. 2024; 11:1378386.
PMID: 38584703 PMC: 10995332. DOI: 10.3389/fmolb.2024.1378386.